Synergy CHC Corp. received a delisting notice from Nasdaq on September 11, 2026, following its voluntary Chapter 11 bankruptcy filing on September 4, 2026. Nasdaq cited public interest concerns and the company's inability to sustain listing compliance as reasons for the decision. Trading of the common stock is suspended at the opening of business on September 18, 2026, with a Form 25-NSE to be filed to remove the securities from the exchange. The company does not intend to appeal this determination. Synergy CHC Corp. operates in the healthcare sector, specifically focusing on chronic health conditions.

Synergy CHC Corp filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the District of Columbia on September 4, 2026 (Case No. 26-465-ELG). The company will operate as a debtor-in-possession and anticipates filing a plan of liquidation or reorganization within 120 days. Concurrently, directors Alfred Baumeler, Nitin Kaushal, J. Paul SoRelle, and Teresa Thompson resigned from the Board effective September 4, 2026, leaving Jack Ross as the sole director. President Alfred Baumeler also resigned on August 31, 2026. Lauren P. Berret of Eisner Advisory Group LLC was engaged as chief restructuring officer effective August 26, 2026. The company operates in the healthcare staffing and consulting industry.

Synergy CHC Corp. received a Notice of Acceleration from ACP Agency, LLC on August 25, 2026, following previously disclosed events of default under its Term Loan Credit Agreement dated May 30, 2025. Acting at the direction of required lenders, ACP terminated all commitments and accelerated outstanding obligations, declaring approximately $18.9 million immediately due and payable as of August 21, 2026, excluding accruing interest, fees, costs, and expenses. This company operates in the healthcare sector, specifically providing clinical research services.

Synergy CHC Corp. received a notice from Nasdaq on August 20, 2026, indicating non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Form 10-Q for the quarter ended June 30, 2026. The company has until October 19, 2026, to submit a compliance plan and may receive an extension up to February 10, 2027, to regain compliance. Nasdaq stated the notice has no immediate effect on listing or trading, but the company cannot assure it will file the report or maintain its status. Synergy CHC Corp. develops and markets consumer health and wellness products.

Synergy CHC Corp. received a notice of default from ACP Agency, LLC on August 11, 2026, following the company's failure to make an interest payment due on August 3, 2026 after its cure period expired on August 6, 2026. The termination of a prior forbearance agreement triggered a $404,173.06 fee and left approximately $17.6 million in principal outstanding under the Term Loan Credit Agreement. ACP has reserved rights to accelerate obligations and exercise other remedies. Synergy CHC Corp. operates in the healthcare staffing industry.

On July 15, 2026, Costco Wholesale Corporation notified Synergy CHC Corp that it will discontinue carrying the Company’s FOCUSfactor products. Costco has been a significant customer for over 16 years and accounted for approximately 58% of net revenue in fiscal year 2025. The Company expects this decision to have a material adverse effect on its business, results of operations, liquidity, and financial condition, and is evaluating financing and strategic alternatives. Synergy CHC Corp operates in the consumer health products industry, manufacturing and selling dietary supplements.